Access Dermatology

Breaking News

• Home »
• Breaking News »
• Breaking News article

Briakinumab is safe and efficacious in phase II and III trials in psoriasis

Data from two clinical studies of briakinumab (ABT-874; Abbott), a fully human monoclonal antibody designed to target and neutralize interleukin-12 (IL-12) and IL-23 for the treatment of patients with moderate to severe psoriasis, were recently presented at the Summer Meeting of the American Academy of Dermatology held in Chicago. A 12-week, randomized, double-blind, placebo-controlled, phase II trial evaluated the safety and efficacy of subcutaneous injections of briakinumab versus placebo in 180 subjects with psoriasis affecting > 10% of their body surface area and exhibiting a Psoriasis Area and Severity Index (PASI) score >= 12 (ClinicalTrials.gov Identifier NCT00292396). Briakinumab was administered at five treatment schedules: a single 200-mg dose at week 0, 100 mg ...